SCHEMBL835071

SCHEMBL835071

CC(C)C[C@H](N)C(O)c1cccc(F)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.44
MIF P14174 1/20 0.44
HTR2A P28223 1/20 0.44
ADRA1A P35348 1/20 0.44
HTR2B P41595 1/20 0.44
AOC3 Q16853 1/20 0.43
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
HDAC4 P56524 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2C P18825 1/20 0.38
LMNA P02545 1/20 0.38
HIF1A Q16665 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL836187 0.98 ADRB1 (0.42) ADRB1MIFHTR2AADRA1AHTR2B
SCHEMBL23619060 0.81 ADRB1 (0.65) ADRB1MIFHTR2AADRA1AHTR2B
SCHEMBL3220098 0.81 ADRB1 (0.65) ADRB1MIFHTR2AADRA1AHTR2B
SCHEMBL13995166 0.80 AOC3 (0.44) AOC3SLC6A2SLC6A4CES2CES1
SCHEMBL6743516 0.79 ADRA2C (0.61) HTR2AADRA1AAOC3SLC6A2SLC6A4
SCHEMBL9449194 0.79 ADRA2C (0.61) HTR2AADRA1AAOC3SLC6A2SLC6A4
SCHEMBL9667227 0.79 CES2 (0.50) ADRB1MIFHTR2AADRA1AHTR2B
SCHEMBL15050757 0.77 CES2 (0.49) ADRB1MIFHTR2AADRA1AHTR2B
SCHEMBL15050759 0.77 CES2 (0.49) ADRB1MIFHTR2AADRA1AHTR2B
SCHEMBL15050756 0.77 CES2 (0.49) ADRB1MIFHTR2AADRA1AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120252770-A1 Chemical Compounds 572 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-04 US disclosed
EP-2102169-B1 INDAZOLYL AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS ASTRAZENECA AB (SE) 2012-06-20 EP disclosed
US-8143290-B2 Chemical compounds 572 ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-20110071194-A1 Chemical Compounds 572 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-03-24 US disclosed
US-20100197644-A1 Chemical Compounds 572 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2010-08-05 US disclosed
US-7728030-B2 Chemical compounds 572 ASTRAZENECA AB (SE) 2010-06-01 US disclosed
US-20080214641-A1 Chemical compounds 572 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214641-A1 Chemical compounds 572 ABCG2, ABCB1, CYP11B2 ADRB1 361/4885MIF 502/4885HTR2A 2340/4885
US-20100197644-A1 Chemical Compounds 572 ABCG2, ABCB1, CYP11B2 ADRB1 361/4885MIF 502/4885HTR2A 2340/4885
US-20120252770-A1 Chemical Compounds 572 ABCG2, ABCB1, CYP11B2 ADRB1 361/4885MIF 502/4885HTR2A 2340/4885
US-20110071194-A1 Chemical Compounds 572 ABCG2, ABCB1, CYP11B2 ADRB1 361/4885MIF 502/4885HTR2A 2340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.